



## Essential Overview and Current Updates in Haematological Conditions and Disorders: A Patient-Centred and Exam-Focused Approach

5<sup>th</sup> April 2020

Postgraduate Centre, Manchester Royal Infirmary, Manchester

## **Programme**

| 0845 – 0900   | Welcome and Introduction  |
|---|---|
| 0900 – 0930   | Abnormal Blood Counts and Increased Paraprotein Levels  |
| 0930 – 1000   | Abnormal Clotting Tests and Management of Bruising  |
| 1000 - 1030   | Diagnosis and Management of Leukaemia and Lymphomas   |
| 1030 – 1050   | Break for Refreshments  |
| 1050 – 1120   | Management of Atrial Fibrillation - Current Guidelines and Controversies  |
| 1150 – 1220   | Indications, Contraindications and Guidance in the Usage of Anti-Platelets and Anti-Coagulants  |
| 1220 - 1250   | Case-Based Panel Discussion; Question and Answer Session  |
| 1250 – 1340   | Lunch   |
|   |   |
| 1340 - 1410   | Clinical Considerations in Managing Bleeding Disorders  |
| 1340 1410<br>1410 1440  | Clinical Considerations in Managing Bleeding Disorders<br>Bleeding and Clotting in Patients with Malignancies   |
|   |   |
| 1410 - 1440   | Bleeding and Clotting in Patients with Malignancies   |
| 1410 - 1440<br>1440 - 1510                                      | Bleeding and Clotting in Patients with Malignancies<br>Clinical Considerations in Sickle Cell Disease & Thalassemia   |
| 1410 – 1440<br>1440 – 1510<br><b>1510 – 1530</b>                | Bleeding and Clotting in Patients with Malignancies<br>Clinical Considerations in Sickle Cell Disease & Thalassemia<br>Break for Refreshments   |
| 1410 – 1440<br>1440 – 1510<br><b>1510 – 1530</b><br>1530 – 1550 | Bleeding and Clotting in Patients with Malignancies<br>Clinical Considerations in Sickle Cell Disease & Thalassemia<br>Break for Refreshments<br>Current Guidance in the Management of DVT and PE<br>Indications for Blood Products (Fresh Frozen Plasma, Prothombin Complex Concentrate, |

www.doctorsacademy.org